111 results about "Mouse Colon" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention belongs to the field of medicines, and provides application of indole-3-formaldehyde in preparation of an enteric nerve protection medicine. A loperamide-induced C57BL / 6J mouse constipation model is adopted, it is found that indole-3-carboxaldehyde can accelerate the small intestine propulsion rate of a model mouse, increase the water content of excrement and the excretion number of excrement particles in unit time and improve the intestinal motility of the model mouse, and HUC / DmRNA expression of mouse colon tissue treated by indole-3-carboxaldehyde is remarkably increased compared with a model group; protein expression of HUC / D and HSP90AA1 is remarkably increased compared with that of a model group, immunohistochemistry and immunofluorescence show that the number of HUC / D dyed neurons and fluorescence intensity of colon tissue treated by indole-3-formaldehyde are remarkably increased compared with that of the model group, and therefore, the indole-3-formaldehyde can promote intestinal motility by protecting HUC / D intestinal neuronal cells.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The invention relates to the field of new application of traditional Chinese medicinal materials, and particularly provides application of ash grass root in preparation of medicine for treating ulcerative colitis, DSS-induced mouse colitis model experiments and UC patient control experiments show that ash grass root has remarkable technical effects in treatment of ulcerative colitis, and the application of ash grass root in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis. The gray couchgrass root shows the effect of relieving inflammatory response, tissue damage and immune disorder related to colitis; the intestinal mucosa repair is promoted; the intestinal barrier function is strengthened; the pathological state of colon tissue is improved; the level of inflammatory factors is reduced; and flora metabolism can be adjusted. The invention provides a new natural medicine source for preventing and treating ulcerative colitis, and has good application value and industrial transformation prospect.

The invention discloses an application of 2, 3-dihydroxybenzoic acid in preparation of an antitumor drug. Researches find that 2, 3-dihydroxybenzoic acid can inhibit proliferation, migration and invasion of colorectal cancer cells in vitro and promote cell cycle arrest and cell apoptosis, and 2, 3-dihydroxybenzoic acid can inhibit growth of mouse transplanted tumors in vivo and promote cell apoptosis; the 2, 3-dihydroxybenzoic acid has a remarkable treatment effect on mouse colon cancer and can improve the immunotherapy effect; moreover, the 2, 3-dihydroxybenzoic acid small molecule substance, as an inhibitor of fatty acid synthase (FASN), plays an important role in inhibiting colorectum.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention discloses EGCG-myricetin carrier-free nanoparticles based on hydrogen peroxide oxidation crosslinking as well as a preparation method and application of the EGCG-myricetin carrier-free nanoparticles. The preparation method comprises the following steps: mixing amino acid, EGCG and hydrogen peroxide for reaction to prepare a covalent skeleton of an EGCG-amino acid network; and subjecting myricetin and the covalent skeleton of the EGCG-amino acid network to self-assembly so as to obtain the EGCG-myricetin carrier-free nanoparticles based on hydrogen peroxide oxidation crosslinking. According to the EGCG-myricetin carrier-free nano-particles disclosed by the invention, complex molecular design and tedious preparation schemes of a current delivery system and potential harmful effects of excipients are avoided, the prepared carrier-free nano-particles have good loading effect, stability and biological safety, and meanwhile, the EGCG-myricetin carrier-free nano-particles can obviously improve mouse colitis symptoms induced by DSS; technical support is provided for developing carrier-free nano-particles and relieving inflammatory bowel diseases, and the carrier-free nano-particles have huge clinical development prospects.

The invention discloses a strain of Shenjing pig combined lactobacillus and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31452. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age and is sensitive to various common antibiotics, and fermented supernate of the strain shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B and gardnerella vaginalis; the compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The invention discloses a spleen-targeted nano platform construction method suitable for tumor vaccination, and particularly relates to the field of vaccines.The spleen-targeted nano platform construction method comprises the steps that S1, CL15H6-DOPS LNPs, spherical polymer vesicles and erythrocyte membrane coated nano-particles are selected as spleen-targeted nano-carriers; s2, integrating an immunologic adjuvant; mn < 2 + > doped LNPs, ultrasonic response lipidosome and a CD3 antibody are selected to be coupled to serve as an integration material; s3, delivering in vivo; animal models are selected for in-vivo delivery and curative effect verification, and B16F10 melanoma mice, MC38 colon cancer mice and non-human primates are selected as the animal models respectively. By optimizing the chain length and the surface topological structure (such as spherical polymer vesicles) of the liposome, the spleen enrichment rate is remarkably increased, and the red marrow myeloid cell uptake efficiency is enhanced. By combining with common delivery of a manganese adjuvant, an STING channel is activated, secretion of type I interferon is promoted, and the proportion of antigen-specific CD8 + T cells and the tumor inhibition rate are increased.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention discloses a lactobacillus jensenii strain and application thereof in fermentation of wall-broken ganoderma lucidum spore powder. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31484. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is sensitive to various common antibiotics, and has strong lactic acid production capacity; a fermentation supernatant of the bacillus subtilis shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae, yersinia enterocolitica and gardnerella vaginalis, and has relatively strong adhesion capability, growth inhibition capability and apoptosis promotion effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

The invention discloses preparation of a methoxyl derivative and application of the methoxyl derivative in pharmacy. The methoxy derivative as shown in the formula I has good anti-tumor activity, and the anti-tumor effect is effectively achieved through the growth inhibition and killing effect on tumor cells. The methoxyl derivative not only can inhibit the growth of CT26 transplanted tumors, but also can promote the activation and infiltration of lymphocytes in an in-vivo tumor microenvironment. Meanwhile, the compound also has a remarkable inhibiting effect on the growth of mouse colon cancer CT26 cell strains in vitro.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

The invention relates to an application of a trichina succinic acid coenzyme A ligase beta-like protein SUCLA-beta. The invention identifies a trichina recombinant protein SUCLA-beta which can be used for preventing or treating colitis. A mouse colitis model is successfully copied, it is proved that the protein can improve intestinal inflammation caused by TNBS, the disease activity indexes of mice treated by the trichina recombinant protein SUCLA-beta in a treatment group or a prevention group are reduced, intestinal injury and inflammation are relieved, the disease activity indexes are gradually reduced along with dosage increase, and the intestinal injury and inflammation are relieved. Intestinal injury and inflammatory symptoms are gradually relieved, and the trichina recombinant protein SUCLA-beta can relieve inflammatory response by adjusting the proportion of Th1 / Th2 / Th17 / Treg cells. The trichina recombinant protein SUCLA-beta has a relatively good application prospect in the aspect of preventing or treating colitis.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The invention provides an application of a heat shock protein 90 inhibitor in preparation of a medicine for treating intestinal injury and complicated intestinal inflammation thereof. The HSP90 inhibitor is suitable for treating colon tissue injury caused by a medicine for inducing Gasdermin E (GSDME) mediated pyroptosis. The HSP90 inhibitor specifically inhibits the expression of GSDME protein in normal intestinal epithelial cells and reduces the sensitivity of the normal intestinal epithelial cells to drug-induced GSDME-mediated pyroptosis, so that the damage to colon tissues is relieved, and the induced inflammatory response of the colon tissues is effectively inhibited. TAS-116 and BIIB021 are used as representative drugs of the HSP90 inhibitor, 4 mg / kg of TAS-116 and BIIB021 are used for a mouse colon injury model constructed by 5-FU and CDDP, and the result shows that the HSP90 inhibitor can obviously improve weight loss and colon tissue injury of mice caused by the drugs, and has a good application prospect. Therefore, the HSP90 inhibitor has remarkable curative effect and application value in the aspect of relieving or preventing and treating intestinal injury caused by drugs.

The invention discloses trichina cathepsin B as well as a coding gene and application thereof, and belongs to the technical field of gene engineering. According to the invention, a food-grade L.lactis expression system is utilized to construct a lactic acid bacteria expression system of a TsCB gene, after the L.lactis recombinant strain pNZ8149-TsCB / L.lactis NZ3900 is subjected to intragastric administration on a mouse, the body can be induced to generate 2-type immune response, the recruitment of M2-type macrophages is increased, the infiltration of neutrophil is reduced, and the expression of proinflammatory factors and inflammatory mediators is inhibited, so that the colitis of the DSS mouse is improved; and a foundation is laid for subsequent research and development of food-grade oral insect-derived molecular medicines for treating colitis.

The present invention discloses an enteric-coated lignin bacterial embedding particle for treating ulcerative colitis and its preparation. Based on the principle of electrostatic interaction, the present invention uses anionic lignin to embed bacteria. Under neutral or weakly alkaline conditions, the surface of the bacteria carries a negative charge. Through electrostatic interaction, a layer of Ca<supgt;2+< / supgt; is adsorbed on the surface of the bacteria, and then Ca<supgt;2+< / supgt; adsorbs anionic lignin to form a nano-coating on the surface of the bacteria, realizing the embedding of the bacteria. The preparation process of the enteric-coated lignin bacterial embedding particle of the present invention is simple. It not only increases the viable count of bacteria in simulated gastric juice and is smoothly released in simulated intestinal juice, but also lignin and the embedded bacteria can play a synergistic therapeutic effect, effectively treating DSS-induced colitis in mice and increasing the colon length of diseased mice, providing new ideas for the development of new oral dosage forms of bacteria, and expanding the high-value application range of lignin, promoting the development and application of biomass resources.

The invention provides a medicine for preventing or treating enteritis. Hamp is adopted; and E, dyeing, determination of IL-6 factors in serum of each group of animals and the like are used for researching the influence of the vocyclosporine on intestinal tissues, mucosal barriers and immune systems of DSS or TNBS-induced mouse colitis models. Experimental basis is provided for clinical application of the vocyclosporine in preparation of the colitis treatment medicine, and the vocyclosporine has good application prospects and huge potential value and social significance.

A polypeptide specifically blocking the binding of ACVR1C to GREM1 is provided. The small-molecule polypeptide interferes with or blocks the binding of GREM1 to ACVR1C in vitro and in vivo. The liver metastasis of colon cancer in mice in a treatment group is significantly lowered, which indicates that the small-molecular polypeptide achieves the blocking of the liver metastasis of colon cancer.

The invention discloses a compound with an anti-inflammatory effect in Enshi Sichuan amur corktree, separation and application, and belongs to the technical field of medicines. The invention particularly discloses a compound which is separated from Enshi chuan amur corktree and has an anti-inflammatory effect, a separation preparation method and application. Researches prove that the compound has an inhibition effect on the expression of inflammatory factors IL-1beta and IL-17A, can inhibit the generation and secretion of an inflammatory factor IL-6 in Th17 cells, can reduce the expression level of Caspase-1 and NLRP3 proteins in colon tissues of mice, and can reduce the inflammatory response of ulcerative colitis of DSS modeling mice in a dose-dependent manner. The compound (limonin compound) with the anti-inflammatory effect in Enshi Huangchuan amur corktree can be used as a lead compound for development of anti-inflammatory drugs, and is of great significance to comprehensive utilization and development of Enshi Huangchuan amur corktree.

The invention discloses an antigen expression vector, a combination of the antigen expression vector and an antibody and application of the combination in cancer treatment. The antigen expression vector comprises one or more DMP-antigen coding gene units; the DMP-antigen coding gene is composed of two functional elements DMP and an antigen coding gene, the DMP is an NF-kappa B specific promoter, and the antigen coding gene is an antigen molecule coding sequence. The antigen expression vector prepared by the invention can selectively express antigen molecules in cancer cells, an in-vivo delivery vector taking adeno-associated virus as the antigen expression vector, and a combination of an antigen CD20 expressed by the antigen expression vector and an anti-CD20 antibody rituximab. The compound has a good treatment effect on mouse colon cancer on mice and human colon cancer on humanized mice, and has good tumor targeting property and safety in the treatment of the cancer mice. The invention is expected to provide a new technology and a new reagent for the treatment of various cancer diseases.

The present invention belongs to the field of microorganisms, and specifically relates to the use of Lactobacillus rhamnosus AFY01 and a product thereof in inflammatory colon cancer. Provided is a strain of Lactobacillus rhamnosus AFY01 with the deposit number of CGMCC No. 27362. The AFY01 can effectively alleviate weight loss in mice with colon cancer and colon shortening caused by intestinal inflammation and edema, reduce the colon coefficient of mice, reduce the visceral index and reduce the occurrence of intestinal tumors in mice, alleviate intestinal inflammation, and promote intestinal tumor cell apoptosis to slow down the development of colon cancer. By means of the present invention, the strain resources are expanded, thus providing technical support for the prevention and treatment of intestinal cancers.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The present application relates to the technical field of microorganism, and particularly relates to a luohanguo flavor dairy product and a preparation method and application thereof, the present application adopts buffalo milk, luohanguo powder, paracasei and rhamnosus to prepare the flavor dairy product, it is found during the preparation process research that the luohanguo powder, paracasei and rhamnosus have good synergies, the luohanguo powder fermented dairy product prepared by the combination has good antioxidant function, through animal experiment, the product can effectively relieve the inflammation of DSS-induced mouse colon, and the effect of the luohanguo flavor fermented milk is close to that of positive drug, so the product is a good diet therapy product.

The present invention discloses the application of polyvinyl alcohol in the preparation of drugs related to the treatment of ulcerative colitis, belonging to the field of pharmaceutical technology. In the present invention, a DSS-induced ulcerative colitis model was established to observe the therapeutic effects of PVA aqueous solutions at different concentrations on the model mice. The degree of damage, inflammation and remission of the mouse colon tissue were evaluated by recording the changes in mouse body weight, clinical disease activity index, colon length, histopathology and inflammatory factor levels; and further, mouse colon organoids were cultured to observe the effects of PVA aqueous solutions at different concentrations on the number of organoids in vitro. The present invention finds that the PVA aqueous solution can relieve ulcerative colitis, improve tissue damage and symptoms, and its mechanism may be related to the promotion of intestinal stem cell expansion by the PVA aqueous solution, and then the promotion of intestinal mucosal damage repair, providing new ideas and methods for the clinical treatment of ulcerative colitis.

The invention discloses polygonum multiflorum polysaccharide, a preparation method and application of the polygonum multiflorum polysaccharide in preparation of a medicine for treating ulcerative colitis. Polygonum multiflorum polysaccharide is obtained through extraction, deproteinization and column chromatography of Polygonum multiflorum. By establishing a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse model to evaluate the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide, it is proved that the polygonum multiflorum polysaccharide has the advantages that the weight of the ulcerative colitis model mouse is remarkably increased, the hemafecia index and the loose stool index are remarkably reduced, the colon length is increased, and the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide is remarkably improved. The richness of intestinal flora is effectively improved, the pathological damage of the colonic tissue of an ulcerative colitis model mouse is effectively improved, and the purpose of treating ulcerative colitis is achieved. Therefore, it is proved for the first time that the polygonum multiflorum polysaccharide has a remarkable ulcerative colitis resisting effect, and an important theoretical basis is provided for development of ulcerative colitis resisting drugs.

The application discloses a method for relieving the adverse effects of chronic restraint stress on animals by adding sodium isovalerate into feed, which comprises taking C57BL / 6J mice as research objects, studying the effects of sodium isovalerate on growth performance, depression behavior and intestinal barrier and inflammation indexes of the mice with chronic restraint stress, recording daily weight gain and feed intake, and performing tail suspension test and Elisa test and other test methods, and proving that sodium isovalerate can relieve the decrease of mouse weight growth rate, the increase of feed to weight ratio and the decrease of organ index caused by CRS; through fluorescence quantitative PCR and Western Blot and other methods, it is proved that sodium isovalerate can relieve the intestinal injury of the CRS mice, reduce the expression of colon pro-inflammatory factors and improve the expression of tight junction proteins, and can also reduce the phosphorylation level of NF-kappa B in the colon of the CRS mice. The application explores the relieving effect of sodium isovalerate on chronic restraint stress of animals, so as to provide some theoretical basis for relieving stress in actual production and the application of sodium isovalerate in feed additives.

The invention provides a construction method of engineered lactic acid bacteria for constitutive expression of SodA protein and application of the engineered lactic acid bacteria in treatment of IBD. The invention provides a construction method of engineered lactic acid bacteria (KI (at) lSodA) for relieving IBD (Infectious Bronchitis Disease) constitutive expression SodA protein. A verification experiment result shows that the KI (at) lSodA highly expresses the SodA protein, and the oxidative stress management capability of the strain is improved; meanwhile, the KI (at) lSodA also has long-term use safety, the treatment of the KI (at) lSodA remarkably relieves the colitis symptoms and in-vivo inflammation conditions of mice in an acute stage, a recovery stage and a chronic state, and the KI (at) lSodA shows a strong intestinal microbial diversity recovery capability in all three experimental models, and particularly shows a remarkable repair effect in a recovery stage model. Therefore, the invention provides a new basis for IBD treatment.